Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory of LEPUS

Fu, WJ; Li, W; Hu, JD; An, G; Wang, YF; Fu, CC; Chen, LJ; Jin, J; Cen, XN; Ge, Z; Cai, Z; Niu, T; Qi, M; Gai, X; Li, Q; Liu, WP; Liu, WY; Yang, X; Chen, X; Lu, J

Lu, J (通讯作者)，Peking Univ, Peoples Hosp, Natl Clin Res Ctr Hematol Dis, Collaborat Innovat Ctr Hematol, 11 Xizhimen South St, Beijing 100044, Peoples R China.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023; 23 (1): E51

Abstract

LEPUS showed significant efficacy benefits with daratumumab plus bortezomib/dexamethasone (D-Vd) versus Vd for Chinese patients with relapsed or refra......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索